About: Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
Creator	Wang, Jen-Ren Huang, Sheng-Wen Wang, Ya-Fang Wang, Y-F Chai, Kit Chai, Man Cheng, Dayna Hsu, C-H Hsu, Yin-Mei Hung, Su-Jhen Kit, Km, Chai Tai, Ching-Hui
source	Elsevier; Medline; PMC
abstract	Highly pathogenic emerging and re-emerging viruses continuously threaten lives worldwide. In order to provide prophylactic prevention from the emerging and re-emerging viruses, vaccine is suggested as the most efficient way to prevent individuals from the threat of viral infection. Nonetheless, the highly pathogenic viruses need to be handled in a high level of biosafety containment, which hinders vaccine development. To shorten the timeframe of vaccine development, the pseudovirus system has been widely applied to examine vaccine efficacy or immunogenicity in the emerging and re-emerging viruses. Here we developed pseudovirus systems for emerging SARS coronavirus 2 (SARS-CoV-2) and re-emerging avian influenza virus H5 subtypes which can be handled in the biosafety level 2 facility. Through the generated pseudovirus of SARS-CoV-2 and avian influenza virus H5 subtypes, we successfully established a neutralization assay to quantify the neutralizing activity of antisera against the viruses. In addition, the result of re-emerging avian influenza virus H5Nx pseudoviruses provided valuable information for antigenic evolution and immunogenicity analysis in vaccine candidate selection. Together, our study assessed the potency of pseudovirus systems in vaccine efficacy, antigenic analysis, and immunogenicity in the vaccine development of emerging and re-emerging viruses. Instead of handling live highly pathogenic viruses in a high biosafety level facility, using pseudovirus systems would speed up the process of vaccine development to provide community protection against emerging and re-emerging viral diseases with high pathogenicity.
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1016/j.bj.2020.06.003
bibo:pmid	32611537
has license	no-cc
sha1sum (hex)	cd0acf9e8f8a440346af06f904587dfb77826ac1
schema:url	https://doi.org/10.1016/j.bj.2020.06.003
resource representing a document's title	Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
has PubMed Central identifier	PMC7274974
has PubMed identifier	32611537
schema:publication	Biomed J
resource representing a document's body	covid:cd0acf9e8f8a440346af06f904587dfb77826ac1#body_text
is schema:about of	named entity 'pseudovirus' named entity 'emerging' named entity 'pseudovirus' named entity 'HIGHLY' named entity 'WORLDWIDE' named entity 'SYSTEM' named entity 'Abstract' named entity 'avian influenza' named entity 'emerging' named entity 'vaccine' named entity 'viruses' named entity 'prophylactic' named entity 'emerging' named entity 'subtypes' named entity 'SARS-CoV-2' named entity 'pseudovirus' named entity 'SARS-CoV-2' named entity 'application' named entity 'recombination' named entity 'BSL-3' named entity 'SARS-CoV-2' named entity 'Competent cell' named entity 'pseudoviruses' named entity 'avian influenza virus' named entity 'H5N2' named entity 'pseudovirus' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'trypsin' named entity 'progeny viruses' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'H5N6' named entity 'virions' named entity 'emerging virus' named entity 'SARS-CoV-2' named entity 'pseudovirus' named entity 'virions' named entity 'trypsin' named entity 'elastase' named entity 'SARS-CoV' named entity 'glycoprotein' named entity 'protein subunit' named entity 'Plasmids' named entity 'antisera' named entity 'antisera' named entity 'virus' named entity 'lentiviral' named entity 'SARS-CoV' named entity 'pseudoviruses' named entity 'transfected' named entity 'midi' named entity 'Taiwan' named entity 'pseudovirus' named entity 'vectors' named entity 'vector' named entity 'lentivirus' named entity 'plasmid' named entity 'SARS-CoV' named entity 'pseudovirus' named entity 'cloned' named entity 'transduced' named entity 'viruses' named entity 'protein' named entity 'replication cycle' named entity 'pseudovirus' named entity 'antisera' named entity 'H5N2' named entity 'avian influenza virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software